Stability and Efficiency of Mixed Aryl Phosphonate Prodrugs

A set of phosphonate prodrugs of a butyrophilin ligand was synthesized and evaluated for plasma stability and cellular activity. The mixed aryl acyloxy esters were prepared either via a standard sequence through the phosphonic acid chloride, or through the more recently reported, and more facile, triflate activation. In the best of cases, this class of prodrugs shows cellular potency similar to that of bis‐acyloxyalkyl phosphonate prodrugs and plasma stability similar to that of aryl phosphonamidates. For example, {[((3E)‐5‐hydroxy‐4‐methylpent‐3‐en‐1‐yl) (naphthalen‐2‐yloxy)phosphoryl]oxy}methyl 2,2‐dimethylpropanoate can activate BTN3A1 in K562 cells after just 15 minutes of exposure (at an EC50 value of 31 nm) and is only partially metabolized (60 % remaining) after 20 hours in human plasma. Other related novel analogues showed similar potency/stability profiles. Therefore, mixed aryl acyloxyalkyl phosphonate prodrugs are an exciting new strategy for the delivery of phosphonate‐containing drugs.

[1]  W. Jacobs,et al.  Immunization of Vγ2Vδ2 T cells programs sustained effector memory responses that control tuberculosis in nonhuman primates , 2019, Proceedings of the National Academy of Sciences.

[2]  J. Gumperz,et al.  Expansion and Adoptive Transfer of Human Vδ2+ T Cells to Assess Antitumor Effects In Vivo. , 2018, Methods in molecular biology.

[3]  A. Wiemer,et al.  A power law function describes the time‐ and dose‐dependency of V&ggr;9V&dgr;2 T cell activation by phosphoantigens , 2018, Biochemical pharmacology.

[4]  C. Riganti,et al.  Vγ9Vδ2 T Cells as Strategic Weapons to Improve the Potency of Immune Checkpoint Blockade and Immune Interventions in Human Myeloma , 2018, Front. Oncol..

[5]  A. Wiemer,et al.  Phosphonamidate Prodrugs of a Butyrophilin Ligand Display Plasma Stability and Potent Vγ9 Vδ2 T Cell Stimulation. , 2018, Journal of medicinal chemistry.

[6]  Haobin Wang,et al.  Direct Aryloxylation/Alkyloxylation of Dialkyl Phosphonates for the Synthesis of Mixed Phosphonates. , 2018, Angewandte Chemie.

[7]  E. Scotet,et al.  Towards Deciphering the Hidden Mechanisms That Contribute to the Antigenic Activation Process of Human Vγ9Vδ2 T Cells , 2018, Front. Immunol..

[8]  H. Jessen.  The Hitchhiker’s Guide to Organophosphate Chemistry , 2018, Synlett.

[9]  P. Jaffrès,et al.  Phosphonic acid: preparation and applications , 2017, Beilstein journal of organic chemistry.

[10]  M. Poe,et al.  Mixed Aryl Phosphonate Prodrugs of a Butyrophilin Ligand. , 2017, ACS medicinal chemistry letters.

[11]  O. Vinogradova,et al.  The butyrophilin 3A1 intracellular domain undergoes a conformational change involving the juxtamembrane region , 2017, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[12]  S. Kenney,et al.  Adoptively transferred Vγ9Vδ2 T cells show potent antitumor effects in a preclinical B cell lymphomagenesis model. , 2017, JCI insight.

[13]  O. Vinogradova,et al.  Phosphinophosphonates and Their Tris-pivaloyloxymethyl Prodrugs Reveal a Negatively Cooperative Butyrophilin Activation Mechanism. , 2017, Journal of Medicinal Chemistry.

[14]  A. Wiemer,et al.  HMBPP Analog Prodrugs Bypass Energy-Dependent Uptake To Promote Efficient BTN3A1-Mediated Malignant Cell Lysis by Vγ9Vδ2 T Lymphocyte Effectors , 2016, The Journal of Immunology.

[15]  M. L. Geng,et al.  Evaluation of a 7‐Methoxycoumarin‐3‐carboxylic Acid Ester Derivative as a Fluorescent, Cell‐Cleavable, Phosphonate Protecting Group , 2016, Chembiochem : a European journal of chemical biology.

[16]  Hong Wang,et al.  Sensor Function for Butyrophilin 3A1 in Prenyl Pyrophosphate Stimulation of Human Vγ2Vδ2 T Cells , 2015, The Journal of Immunology.

[17]  J. Trowsdale,et al.  Activation of Human γδ T Cells by Cytosolic Interactions of BTN3A1 with Soluble Phosphoantigens and the Cytoskeletal Adaptor Periplakin , 2015, The Journal of Immunology.

[18]  A. Wiemer,et al.  Prodrugs of phosphonates and phosphates: crossing the membrane barrier. , 2015, Topics in current chemistry.

[19]  O. Vinogradova,et al.  Synthesis of a phosphoantigen prodrug that potently activates Vγ9Vδ2 T-lymphocytes. , 2014, Chemistry & biology.

[20]  A. Wiemer,et al.  Opportunities and challenges in development of phosphoantigens as Vγ9Vδ2 T cell agonists. , 2014, Biochemical pharmacology.

[21]  James E. Crooks,et al.  The intracellular B30.2 domain of butyrophilin 3A1 binds phosphoantigens to mediate activation of human Vγ9Vδ2 T cells. , 2014, Immunity.

[22]  K. Błażewska.  McKenna reaction--which oxygen attacks bromotrimethylsilane? , 2014, The Journal of organic chemistry.

[23]  E. Adams,et al.  Key implication of CD277/butyrophilin-3 (BTN3A) in cellular stress sensing by a major human γδ T-cell subset. , 2012, Blood.

[24]  Hong Wang,et al.  Nonpeptide antigens, presentation mechanisms, and immunological memory of human Vγ2Vδ2 T cells: discriminating friend from foe through the recognition of prenyl pyrophosphate antigens , 2007, Immunological reviews.

[25]  M. Rogers,et al.  Cytosolic Entry of Bisphosphonate Drugs Requires Acidification of Vesicles after Fluid-Phase Endocytosis , 2006, Molecular Pharmacology.

[26]  William A. Lee,et al.  Metabolism and Pharmacokinetics of Novel Oral Prodrugs of 9-[(R)-2-(phosphonomethoxy)propyl]adenine (PMPA) in Dogs , 1997, Pharmaceutical Research.

[27]  J. Shaw,et al.  Pharmacokinetics and metabolism of selected prodrugs of PMEA in rats. , 1997, Drug metabolism and disposition: the biological fate of chemicals.

[28]  E. De Clercq,et al.  Antiretroviral activity and pharmacokinetics in mice of oral bis(pivaloyloxymethyl)-9-(2-phosphonylmethoxyethyl)adenine, the bis(pivaloyloxymethyl) ester prodrug of 9-(2-phosphonylmethoxyethyl)adenine , 1996, Antimicrobial agents and chemotherapy.

[29]  E. De Clercq,et al.  Intracellular delivery of bioactive AZT nucleotides by aryl phosphate derivatives of AZT. , 1993, Journal of medicinal chemistry.

[30]  F. Westheimer.  Why nature chose phosphates. , 1987, Science.

[31]  N. Leonard,et al.  Synthesis of 3-(2'-deoxy-D-erythro-pentofuranosyl)adenine. Application of a new protecting group, pivaloyloxymethyl(Pom) , 1967 .